EGFR and non-small cell lung carcinoma: In the last few years, there have been many EGFR TKIs (tyrosine kinase inhibitors) approved for the treatment of NSCLC (non-small cell lung cancer), including indole-based FDA-approved EGFR inhibitors such as torceranib (III) (Fig. 1) [24].